达格列净对基線KDIGO风险分类下肾脏和心血管结局的影响:DAPA-CKD试验的事后分析
DAPA-CKD试验事后分析按基线KDIGO风险分类评估达格列净对肾脏和心血管结局的疗效与安全性。达格列净降低主要复合终点风险(HR 0.61;95%CI 0.51, 0.72),且在各KDIGO风险分类间一致(交互作用p均>0.09)。绝对风险降低在各分类间也一致(交互作用p=0.26),不良事件相对频率相似。
要点
- 达格列净降低主要复合终点风险HR 0.61(95%CI 0.51, 0.72)。
- 各KDIGO风险分类间疗效一致,交互作用p均>0.09。
- 绝对风险降低与不良事件频率在各KDIGO风险分类间相似。
核心结论
- 达格列净对肾脏和心血管结局的获益在各KDIGO风险分类间一致,表明其在广泛肾脏疾病严重程度范围内有效且安全。
研究设计与样本
- DAPA-CKD为双盲、安慰剂对照试验,随机分配eGFR 25-75 ml min-1 [1.73 m]-2且UACR≥22.6且<565.0 mg/mmol(200-5000 mg/g)的患者至达格列净10 mg/天或安慰剂。
- 共4304例参与者,按基线KDIGO风险分类:中高风险619例(14.4%)、高风险1349例(31.3%)、极高风险2336例(54.3%)。
- 采用Cox比例风险回归分析评估达格列净在各KDIGO风险分类间的相对和绝对效应。
主要发现
- 达格列净降低主要复合终点风险(HR 0.61;95%CI 0.51, 0.72),各KDIGO风险分类间一致(交互作用p均>0.09)。
- 主要结局的绝对风险降低在各KDIGO风险分类间一致(交互作用p=0.26)。
- 在合并与不合并2型糖尿病的患者中分别分析,达格列净对主要结局的相对风险降低在各KDIGO风险分类亚组间一致。
- 不良事件和严重不良事件的相对频率在各KDIGO风险分类间相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney disease, hospitalised heart failure or cardiovascular death, and death from all causes in patients with chronic kidney disease (CKD) with or without type 2 diabetes. Patients with more severe CKD are at higher risk of kidney failure, cardiovascular events and all-cause mortality. In this post hoc analysis, we assessed the efficacy and safety of dapagliflozin according to baseline Kidney Disease Improving Global Outcomes (KDIGO) risk categories. METHODS: DAPA-CKD was a double-blind, placebo-controlled trial that randomised patients with an eGFR of 25-75 ml min-1 [1.73 m]-2 and urinary albumin/creatinine ratio (UACR) of ≥22.6 and <565.0 mg/mmol (200-5000 mg/g) to dapagliflozin 10 mg/day or placebo. The primary endpoint was a composite of ≥50% reduction in eGFR, end-stage kidney disease (ESKD), and death from a kidney or cardiovascular cause. Secondary endpoints included a kidney composite (≥50% reduction in eGFR, ESKD and death from a kidney cause), a cardiovascular composite (heart failure hospitalisation or cardiovascular death), and death from all causes. We used Cox proportional hazards regression analyses to assess relative and absolute effects of dapagliflozin across KDIGO risk categories. RESULTS: Of the 4304 participants in the DAPA-CKD study, 619 (14.4%) were moderately high risk, 1349 (31.3%) were high risk and 2336 (54.3%) were very high risk when categorised by KDIGO risk categories at baseline. Dapagliflozin reduced the hazard of the primary composite (HR 0.61; 95% CI 0.51, 0.72) and secondary endpoints consistently across KDIGO risk categories (all p for interaction >0.09). Absolute risk reductions for the primary outcome were also consistent irrespective of KDIGO risk category (p for interaction 0.26). Analysing patients with and without type 2 diabetes separately, the relative risk reduction with dapagliflozin in terms of the primary outcome was consistent across subgroups of KDIGO risk categories. The relative frequencies of adverse events and serious adverse events were also similar across KDIGO risk categories. CONCLUSION/INTERPRETATIONS: The consistent benefits of dapagliflozin on kidney and cardiovascular outcomes across KDIGO risk categories indicate that dapagliflozin is efficacious and safe across a wide spectrum of kidney disease severity. TRIAL REGISTRATION: ClinicalTrials.gov NCT03036150. FUNDING: The study was funded by AstraZeneca.
引用
- Waijer SW, Vart P, Cherney DZI, et al. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia. 2022. PMID: 35445820. doi:10.1007/s00125-022-05694-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。